Enliven Therapeutics Inc.
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversibl… Read more
Enliven Therapeutics Inc. (ELVN) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: -0.034x
Based on the latest financial reports, Enliven Therapeutics Inc. (ELVN) has a cash flow conversion efficiency ratio of -0.034x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-15.84 Million) by net assets ($459.49 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Enliven Therapeutics Inc. - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Enliven Therapeutics Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Enliven Therapeutics Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Enliven Therapeutics Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hanma Technology Group Co Ltd
SHG:600375
|
-0.016x |
|
Mabwell (Shanghai) Bioscience Co. Ltd. A
SHG:688062
|
-0.073x |
|
0P0O
LSE:0P0O
|
N/A |
|
Visionox Technology Inc
SHE:002387
|
0.126x |
|
Upbound Group Inc.
NASDAQ:UPBD
|
0.172x |
|
CVS Group plc
PINK:CVSGF
|
0.147x |
|
Karoon Energy Ltd
PINK:KRNGY
|
0.247x |
|
MLS Co Ltd
SHE:002745
|
0.010x |
Annual Cash Flow Conversion Efficiency for Enliven Therapeutics Inc. (2017–2025)
The table below shows the annual cash flow conversion efficiency of Enliven Therapeutics Inc. from 2017 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $459.49 Million | $-70.30 Million | -0.153x | +35.23% |
| 2024-12-31 | $309.85 Million | $-73.19 Million | -0.236x | +5.19% |
| 2023-12-31 | $245.91 Million | $-61.27 Million | -0.249x | -159.67% |
| 2022-12-31 | $-76.83 Million | $-32.08 Million | 0.418x | +333.19% |
| 2021-12-31 | $106.86 Million | $-19.13 Million | -0.179x | -77.26% |
| 2020-12-31 | $84.44 Million | $-8.53 Million | -0.101x | +86.65% |
| 2019-12-31 | $28.92 Million | $-21.88 Million | -0.757x | +49.38% |
| 2018-12-31 | $5.87 Million | $-8.78 Million | -1.494x | -48.63% |
| 2017-12-31 | $8.74 Million | $-8.79 Million | -1.005x | -- |